
John brings over two decades of expertise in biopharmaceutical research, business development, and cross-border licensing. A graduate of Shanghai Medical University, John began their career with 14 years of research experience in oncology at Bristol Myers Squibb and CNS at Wyeth.
Building on this scientific foundation, John transitioned in
John brings over two decades of expertise in biopharmaceutical research, business development, and cross-border licensing. A graduate of Shanghai Medical University, John began their career with 14 years of research experience in oncology at Bristol Myers Squibb and CNS at Wyeth.
Building on this scientific foundation, John transitioned into business development roles within China’s leading CROs, including WuXi AppTec and CrownBio, where they led strategic partnerships and client expansion.
For the past eight years, John has focused on both in-licensing and out-licensing deals across the U.S. and China, facilitating high-impact transactions and acting as a key connector in the global biotech ecosystem.

Anna brings a unique global perspective to biopharma, holding an M.D. in Clinical Pathology and Gynecologic Oncology from the Medical University of Vienna, following undergraduate studies at Peking University Health Science Center and the University of Vienna. With a background that includes leadership roles at Vienna General Hospital and
Anna brings a unique global perspective to biopharma, holding an M.D. in Clinical Pathology and Gynecologic Oncology from the Medical University of Vienna, following undergraduate studies at Peking University Health Science Center and the University of Vienna. With a background that includes leadership roles at Vienna General Hospital and as an SVP at Whale Imagine, Inc., she is also a prominent early-stage investor. Anna currently chairs the Global Surgical Doctors Foundation and serves as Director and Chairman of the American Chinese Medical Alliance, alongside her role as Director of North American 100 Angel Investment LLC. dedication of our team and supporters.

Lucia is a seasoned biopharma leader, holding a PhD and DBA, with Harvard postdoctoral training and extensive hands-on research experience spanning oncology biomarker discovery, RNA therapeutics, and preclinical development. She brings critical regulatory expertise, including IND preparation and eCTD submissions to the FDA. Renowned for h
Lucia is a seasoned biopharma leader, holding a PhD and DBA, with Harvard postdoctoral training and extensive hands-on research experience spanning oncology biomarker discovery, RNA therapeutics, and preclinical development. She brings critical regulatory expertise, including IND preparation and eCTD submissions to the FDA. Renowned for her ability to assess pipelines, make strategic go/no-go decisions, and foster cross-functional collaboration, Dr. [Name] is instrumental at NAPPA in evaluating pipeline assets and guiding investment decisions. Her entrepreneurial spirit and senior management experience in building multi-stakeholder partnerships align perfectly with NAPPA's mission to drive real outcomes in global biopharma ventures.
NAPPA
Copyright © 2026 NAPPA - All Rights Reserved.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.